Evidence map›Paper›PMID 42259784›Full record

ArticleCell death & disease2026

Long-term inhibition of lysosomal glucocerebrosidase activity promotes GPX4 stability and inhibits ferroptosis in dopaminergic neurons.

Marie-Amandine Bonte, Flore Gouel, Aurélie Jonneaux, Karim Belarbi, David Devos, Jean-Christophe Devedjian

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marie-Amandine BonteDépartement de Pharmacologie Médicale, Université de Lille, LilNCog - Lille Neuroscience & Cognition, Equipe TREAT, INSERM UMRS_1172, CHU Lille, LICEND COEN Center, Lille, France. bontemarieamandine@gmail.com.ORCID http://orcid.org/0009-0008-0969-2441
Flore Gouel *Département de Pharmacologie Médicale, Université de Lille, LilNCog - Lille Neuroscience & Cognition, Equipe TREAT, INSERM UMRS_1172, CHU Lille, LICEND COEN Center, Lille, France.
Aurélie JonneauxDépartement de Pharmacologie Médicale, Université de Lille, LilNCog - Lille Neuroscience & Cognition, Equipe TREAT, INSERM UMRS_1172, CHU Lille, LICEND COEN Center, Lille, France.
Karim BelarbiDépartement de Pharmacologie Médicale, Université de Lille, LilNCog - Lille Neuroscience & Cognition, Equipe TREAT, INSERM UMRS_1172, CHU Lille, LICEND COEN Center, Lille, France.ORCID http://orcid.org/0000-0002-0027-1172
David Devos *Département de Pharmacologie Médicale, Université de Lille, LilNCog - Lille Neuroscience & Cognition, Equipe TREAT, INSERM UMRS_1172, CHU Lille, LICEND COEN Center, Lille, France.
Jean-Christophe Devedjian *Département de Pharmacologie Médicale, Université de Lille, LilNCog - Lille Neuroscience & Cognition, Equipe TREAT, INSERM UMRS_1172, CHU Lille, LICEND COEN Center, Lille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An increasing number of studies indicate that ferroptosis, a lethal pathway initiated by excessive iron-dependent lipid peroxidation, and pivotal to the survival of dopaminergic neurons and the progression of Parkinson's disease (PD), may be regulated by the lysosomal pathway. Mutation and loss of function of the lysosomal enzyme, glucocerebrosidase, induce the accumulation of glycosphingolipids and alterations in lysosome activity, which have been associated with a higher risk of developing PD. Our present study showed that transient inhibition of glucocerebrosidase activity had a positive effect on lipid peroxidation and ferroptosis. In a dopaminergic cell line (LUHMES cells), it was shown that a 10-day inhibition of glucocerebrosidase activity using conduritol-beta-epoxide (CBE) specifically impeded susceptibility to RSL3-induced ferroptosis, but not to several other inducers of cell death. CBE impaired the lysosomal pathway, modified lipid membrane composition by reducing ether-linked phospholipids in phosphatidylethanolamines, and promoted an increase in glutathione peroxidase 4 (GPX4) protein levels. This phenomenon was transient and disappeared after 20 days of glucocerebrosidase inhibition, suggesting that the cells have the capacity to return to their basal homeostasis. Most of the current compounds acting on GPX4 promote its degradation, thus information on drugs leading to GPX4 stability is key in order to protect neurons against excessive lipid peroxidation occurring in neurodegenerative diseases.

Indexed as

Dopaminergic NeuronsFerroptosisGlucosylceramidaseLysosomesPhospholipid Hydroperoxide Glutathione PeroxidaseAnimalsCarbolinesCell LineHumansInositolLipid PeroxidationMiceCarbolinesconduritol epoxideGlucosylceramidaseInositolPhospholipid Hydroperoxide Glutathione PeroxidaseRSL3 compound

Identifiers

PMID42259784
PMCPMC13470012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.